SEATTLE, WA — August 6, 2025 — Leads & Copy — Sana Biotechnology, Inc. (Nasdaq: SANA) has announced the commencement of an underwritten public offering of $75.0 million of shares of its common stock. Certain investors will receive pre-funded warrants to purchase shares of its common stock in lieu of common stock. Sana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock.
The offering is subject to market conditions, and there is no assurance as to whether or when the offering may be completed or as to its actual size or terms. Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the proposed offering.
The offering is being made pursuant to a Registration Statement on Form S-3 previously filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus can be accessed for free through the SEC’s website.
This press release does not constitute an offer to sell or a solicitation of an offer to buy securities.
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.
Contact:
Nicole Keith
investor.relations@sana.com
media@sana.com
Source: Sana Biotechnology
